Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2013. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) regarding their personal holdings of the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
The filing details an increase in share interests for specific directors and connected persons following the re-investment of dividends paid on April 11, 2013. The transactions occurred at a price of 1,564.5719 pence per Ordinary Share.
- Sir Andrew Witty: Acquired 2,661 shares.
- Lady C Witty (Connected Person): Acquired 2,016 shares.
- Mr I W Whyte (Connected Person): Acquired 128 shares.
- Mrs V A Whyte: No change in holdings.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of director shareholdings in compliance with Disclosure and Transparency Rules 3.1.4R(1)(a) and (c).
Investor Verification Points
- Verify the dividend reinvestment price of 1,564.5719 pence per share against market data for April 11, 2013.
- Confirm the total shareholding positions of Sir Andrew Witty and connected persons post-transaction.
- Review the company's broader financial reports (e.g., Form 20-F) for comprehensive financial metrics not included in this specific 6-K filing.